X

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia and Richter’s Transformation

RIC-HSCT yields favorable outcomes for patients with high-risk CLL-RT, especially when performed in early remission.

Blood Advances
07/23/2021
Fixed-Dose, First-Line Ibrutinib/Venetoclax Combination Achieves Durable Remissions in CLL

The combination of fixed-duration, first-line treatment with ibrutinib plus venetoclax achieved complete responses in more than half of patients with CLL/SLL, based on the primary analysis...

The ASCO Post
07/10/2021
Immunomodulatory Effects of Different Intravenous Immunoglobulin Preparations in Chronic Lymphocytic Leukemia

This study aims to evaluate the capacity of Pentaglobin and a standard IVIg preparation to affect leukemic and T cells from CLL patients.

Scientific Reports
06/21/2021

Targeted PI3K/AKT-Hyperactivation Induces Cell Death in Chronic Lymphocytic Leukemia

Study investigators test the hypothesis that targeted hyperactivation of the phosphatidylinositol-3-phosphate/AKT-signaling pathway may be leveraged to trigger CLL cell death. 

Nature Communications
06/10/2021
Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients

In the current study, investigators observe an increased percentage of Tie2-expressing monocytes in CLL patients.

Cancers
06/05/2021
​First-in-Human Study of Novel BCL-2 Inhibitor in R/R CLL

Lisaftoclax, a novel BCL-2 inhibitor, was well-tolerated with no significant new or unmanageable safety findings among patients with CLL and other hematologic malignancies...

Oncology Times - Latest Articles
06/11/2021
Utilizing a Unique Cellular Therapeutic in Chronic Lymphocytic Leukemia​

Researchers show—for the first time—that peripheral blood mononuclear cells from CLL patients can be converted into SUPLEXA cells, according to findings presented at ASCO 2021.

Oncology Times - Latest Articles
06/07/2021
Four Year Follow-Up From the Phase III Elevate-TN Trial of CLL Patients

Four-year follow-up of the Phase III Elevate-TN study demonstrates the efficacy and safety of acalabrutinib plus obinutuzumab and acalabrutinib monotherapy is maintained among CLL patients...

Oncology Times - Latest Articles
06/06/2021
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells

Using originally designed BTK PROTAC compounds, study investigators show efficient BTK degradation in chronic lymphocytic leukemia cells.

Frontiers in Oncology
05/13/2021
miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: An Axis Affected by BCR Inhibitors

miR-29 down-modulation in an intraclonal CLL subpopulation from immune niches allows for higher TRAF4 and increased CD40 responsiveness.

Blood
05/06/2021
GENUINE Improvements: Ublituximab Plus Ibrutinib for CLL

Results from the phase 3 GENUINE trial show that ublituximab plus ibrutinib is superior to ibrutinib alone for patients with relapsed or refractory high-risk CLL.

Medscape
04/20/2021
Responses to Conjugate Pneumococcal Vaccine in Patients With Chronic Lymphocytic Leukemia

Mauro et al found that only a small minority of patients with CLL developed an adequate immune response to pneumococcal vaccination, with response being more likely in patients who...

The ASCO Post
03/11/2021
Proteomic and Bioinformatic Profiling of Neutrophils in CLL Reveals Functional Defects That Predispose to Bacterial Infections

This study describes a molecular signature of neutrophils through proteomic, bioinformatic, and functional analyses linked to a reduced migratory ability, that could lead to increased...

Blood Advances
03/02/2021
Ustekinumab-Induced Chronic Lymphocytic Leukemia in a Patient With Psoriatic Arthritis

This is a case report on the development of chronic lymphocytic leukemia in a patient with PsA treated with ustekinumab.

Reumatologia
02/28/2021
Tissue Factor Pathway Inhibitor Upregulates CXCR7 Expression and Enhances CXCL12-Mediated Migration in Chronic Lymphocytic Leukemia

This study aims to explore the role of TFPI in CXCL12-mediated migration of CLL cells.

Scientific Reports
03/04/2021
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia

Long-term follow-up is needed, but zanubrutinib holds promise to be an effective therapy for CLL with a manageable side effect profile and will be an exciting addition to the treatment paradigm.

Drug Design, Development and Therapy
03/02/2021
Preclinical Evaluation of the Hsp90 Inhibitor SNX-5422 in Ibrutinib Resistant CLL

This study explores the efficacy of the Hsp90 inhibitor, SNX-5422, in CLL.

Journal of Hematology & Oncology
02/24/2021
Non-Coding RNAs: The “Dark Side Matter” of the CLL Universe

This review summarizes the main ncRNAs discovered in CLL and the molecular mechanisms by which they are affected and how they influence the development and the progression of the disease.

02/21/2021
The Role of Acalabrutinib in Adults With Chronic Lymphocytic Leukemia

The two major classes of drugs that have contributed to this dramatic evolution include the Bruton tyrosine kinase inhibitors and BCL2 inhibitors.

Therapeutic Advances in Hematology
02/05/2021
An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient With Chronic Lymphocytic Leukemia

This case recapitulates the challenges in diagnosing and treating B-PLL. 

Journal of Investigative Medicine High Impact Case Reports
02/03/2021
Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia

Treatment of patients with CLL harbouring TP53-deficiency requires drugs that promote cell death independently of TP53. 

Cancer Management and Research
02/12/2021
Low Expression of ZHX1 and ZHX2 Impacts on the Prognosis of Chronic Lymphocytic Leukemia

This study determines whether the altered expression of ZHX1 and ZHX2 has clinical implications in patients with CLL.

02/04/2021
Assessing Technical and Biological Variation in SWATH-MS-Based Proteomic Analysis of Chronic Lymphocytic Leukaemia Cells

This study provides a valuable resource for researchers working on the proteomics of CLL.

Scientific Reports
02/03/2021
Genome-Wide Association Study Identifies Risk Loci for Progressive Chronic Lymphocytic Leukemia

This work identifies rs736456 and rs3778076 as prognostic in CLL, demonstrating that disease progression is determined by constitutional genetic variation as well as known somatic drivers.

01/28/2021
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?

This review outlines the impacts of PI3K inhibition on the tumor microenvironment with a specific focus on CLL.

Frontiers in Immunology
01/20/2021
T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword

The T cells in CLL exhibit a distinctive phenotype with features of “exhaustion” likely as a result of chronic antigenic stimulation.

Frontiers in Immunology
01/20/2021
Telomere Dysfunction in Chronic Lymphocytic Leukemia

In chronic lymphocytic leukemia, telomere length is an independent prognostic factor and short telomeres are associated with adverse outcome.

Frontiers in Oncology
01/15/2021
HELQ and EGR3 Expression Correlate With IGHV Mutation Status and Prognosis in Chronic Lymphocytic Leukemia

This study investigates the transcriptomic signatures associating with IGHV mutation status and CLL prognosis.

01/23/2021
Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects

The purpose of this study is to understand how variations in attributes impact treatment choice among patients and oncologists.

01/22/2021
May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia

Study investigators present our clinical experience about ibrutinib use in ARDS secondary to SARS-CoV-2 in a patient with chronic lymphocytic leukemia.

01/15/2021
Recurrent XPO1 Mutations Alter Pathogenesis of Chronic Lymphocytic Leukemia

Exportin 1 is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia.

01/15/2021
The Calcitriol/Vitamin D Receptor System Regulates Key Immune Signaling Pathways in Chronic Lymphocytic Leukemia

This study seeks to obtain deeper biological insight into the role of vitamin D in the pathophysiology of CLL.

Cancers
01/14/2021
Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response

Low expression of miR-181b in chronic lymphocytic leukemia is linked to progression and cell death resistance.

Cancers
01/12/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834